PIK3CA and non-small cell lung carcinoma: However, in the phase II BASALT-1 study: 63 patients (30 squamous and 33 non-squamous) with activated PI3K pathway, metastatic, squamous or non-squamous NSCLC, who failed previous antineoplastic therapies (chemotherapy for squamous or systemic antineoplastic for non-squamous) received buparlisib (100 mg/day) for 12 weeks.